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Abstract 
BACKGROUND: Twist2 is a transcription factor and an epithelial-to-mesenchymal transition that plays an 
important role in cell polarity, cell adhesion, and has a role in tumour invasion and metastases.  
AIM: In this study, we examined the expression of Twist2 in non-muscle invasive bladder carcinoma (NMIBC) and 
correlated the expression with response to treatment and tumour progression. 
METHODS: Data of 305 patients with NMIBC of Ta, T1 were retrieved from hospitals archives. Twist2 expression 
was examined in tissue samples by immunohistochemistry at initial diagnosis and final follow-up, normal control 
was 10 normal urothelium, 10 patients with muscle-invasive bladder cancer (MIBC) were a positive control. 
Treatment of NMIBC was implemented according to the European Association of Urology guidelines on NMIBC. 
The descriptive statistical analysis included means, standard deviation, p-value; Univariate and multivariate Cox 
regression analyses.  
RESULTS: Twist2 expression score was identified as negative, low (1-15%); medium (15-40%); and high (40-
100%). Patients who had low or low medium scores at the initial diagnosis had a good response and a favourable 
prognosis. Expression of a high score of Twist2 in patients having high-grade T1 tumours showed non-
responsiveness to repeated courses of intravesical bacillus Calmette Guerin (BCG) therapy and was upstaged to 
MIBC. 
CONCLUSION: Twist2 expression in tissue samples of NMIBC would indicate the tumour response to therapy, 
upgrading and upstaging in the follow up after intravesical BCG therapy.  
 
 
 
 
 
 
 
Introduction 
 
Bladder cancer (BCa) is seventh cancer in the 
male population, 75% of patients with BCa present at 
initial diagnosis with non-muscle invasive bladder 
cancer (NMIBC) of stage Ta and T1 respectively [1]. 
Muscle invasive bladder cancer (MIBC) of stages T2-
T4 has the potential of lymph nodes invasion and 
distant metastases. High-grade Ta and T1 tumours 
have a high potential for recurrence and upstaging to 
MIBC. The twist is a basic helix-loop-helix 
transcription factor, two Twist-like proteins, Twist1 and 
Twist2, are sharing structural details, the N-termini of 
both Twists is different where Twist1 lacks glycine-rich 
region that consequently leads to a different function 
of Twist2 [2]. The epithelial-mesenchymal transition 
(EMT) leads to the loss of cell polarity and cellular 
adhesion that facilitates cancer cells migration, 
invasion, and metastases in different types of cancer 
including BCa. Twist2 is a regulator of EMT that has 
an important role in tumorigenesis where malignant 
cells acquire the ability of invasion, metastasis in 
addition to resisting cancer therapy [3] [4] [5]. In 
breast cancer, Twist2 expression was significantly 
increased, the cytoplasmic Twist2 in cancer cells at 
the tumour centre of primary carcinomas contributes 
to the maintenance of epithelial cancer characteristics, 
invasion and metastasis. Heterogeneous expression 
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of Twist2 in tumours may have a functional link to 
tumour progression, Twist2 promotes breast cancer 
invasion through loss of E-cadherin, and there is a 
strong link between nuclear Twist2 represented as 
nuclear positivity with an overexpression score and 
cancer progression and metastases [6] [7]. EMT 
process depends on Twist2 cellular location [5]. EMT 
is a dynamic process in the pathogenesis of BCa, 
despite significant advancements in diagnosis and 
treatment, the outcomes remained more or less the 
same. Expression of EMT markers E-cadherin, N-
cadherin, Vimentin, Snail, Twist, Zeb, and Slug in BCa 
showed that increased expression of EMT 
transcription factors correlated significantly with 
tumour grade and stage; therefore EMT marker profile 
would provide a sensitive and effective prognostic tool 
for investigation of BCa [8]. Expression levels of EMT 
markers Twist in tumour specimens taken by 
transurethral resection of bladder tumour of patients 
with NMICB and measured by 
immunohistochemistry(IHC) staining showed that 
expression level was significant predictors of 
intravesical recurrence-free survival, the nuclear 
positivity of Twist2 related to recurrence and 
progression [8]. In a Long-term follow-up of the patient 
to determine whether EMT related markers can 
predict patient survival and progression in NMIBC, it 
was shown that EMT markers E-cadherin, Twist, and 
Vimentin detected by IHC had statistically significant 
correlations with grade, recurrence, tumour 
progression, and progression-free survival [9]. The 
twist is considered as a potential oncogene promoting 
the proliferation and inhibiting the apoptosis in BCa; it 
promotes the synthesis of a pro-angiogenic factor, a 
vascular endothelial growth factor which is involved in 
tumour progression and metastasis [10]. Upregulation 
of Twist2 was related to the aberrant expression of E-
cadherin and the increased expression of Vimentin, 
which were reported as important indicators of EMT. 
Twist2 regulates EMT by depriving the epithelial cell 
phenotype of E-cadherin and endowing the 
mesenchymal cell phenotype with Vimentin, which 
may be involved in the progression and prognosis 
[11].
 
Tumour progression in colorectal cancer was 
significantly correlated to overexpression of Twist2 
and Twist1 [12]. Twist2 expression was correlated to 
the progression of cervical cancer [13]. The purpose 
of this study was to determine whether Twist 2 
upregulation was the promoter of NMIBC not to 
respond to intravesical bacillus Calmette Guerin 
therapy (BCG) and whether the overexpression was 
correlated positively with recurrence and upstaging. 
The goal of this study was to evaluate Twist2 
expression by IHC in order to track disease response 
and progression during therapy, as well as the 
evaluation of association between Twist2 value and 
the clinical outcome, and/or determination of whether 
Twist2 expression contributes to providing additional 
information about the likely clinical outcome beyond 
the information provided by clinicopathological data. 
 
Material and Methods  
 
A cohort of the study was 305 patients with 
NMIBC whom tumour samples were stored in tumour 
archives; the study ran between the years 2008 and 
2016. Patient’s clinical data were analysed, and the 
selection was made for those who had at least 3 years 
of potential follow-up or had frequent recurrences, 
upgrading or upstaging to MIBC that indicated 
immediate cystectomy, inclusion criteria were no 
metastatic disease at diagnosis, any previous 
chemotherapy or radiotherapy. Ten patients with 
MIBC tumours were considered as positive control, 10 
patients who had benign prostatic hyperplasia and 
undergone trans-urethral resection of the prostate 
(TURP) and had no associated cancer were taken as 
negative control.  
The institutional review board approved the 
study and patients gave informed consent to use the 
medical data; the study was to evaluate tumour 
markers in diagnosis and follow-up for NMIBC.  
Patients were adults aged from 32 to 83 
years, diagnosis of NMIBC was based on urine 
cytology, abdominal ultrasound, non-contrast 
computed tomography of the urinary tract, cystoscopy 
and transurethral resection of bladder tumours 
(TURB), pathological diagnosis of NMIBC was made 
by two independent pathologists. Patients received 
treatment in accordance with the European 
Association of Urology guidelines for the treatment of 
NMIBC [14], patients who had low papillary grade Ta 
tumors were treated with TURB, recurrent low-grade 
Ta and low-grade T1 tumors were treated with 
complete TURB and 1 year of full-dose BCG 
treatment, patients with recurrent tumours with high 
grade and high-risk tumours, a full-dose of intravesical 
BCG for 1–3 years were indicated. Tumour 
progression to a higher grade or upstaging an 
immediate cystectomy was done. Follow up was done 
with urine cytology and cystoscopy and biopsy every 3 
months for 36 months, patients who had a recurrence 
after the first course underwent a re-TURB and 
second course of intravesical BCG. Patients showed 
repeated recurrence, upgrading, or upstaging to 
muscle-invasive bladder cancer categorised as non-
responder to BCG intravesical therapy. 
 
Patients characteristics 
A group of 305 patients with NMIBC who had 
been treated with either TURB alone for low papillary 
grade Ta a tumour, or TURB and Intravesical 
intravesical BCG for patients with high-grade Ta, and 
for T1 tumours, follow-up took place for 3 years. 
Patients were categorized into 4 groups; low grade Ta 
(n = 32) were group 1, high grade Ta (n = 67) were 
group 2, low grade T1 (n = 47) were group 3, high 
grade T1 (n = 114) were group 4 (Table 1).  
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Table 1: Demographic and Clinical Characteristics of patients 
having Ta-T1 non-muscle invasive bladder carcinoma at 
baseline and at follow-up following treatment with TURB* and 
BCG‡ 
________________________________________________________________________ 
Features 
Ta, Low 
grade  
Ta,High grade T1,low grade  T1, high grade  
________________________________________________________________________ 
Number 32 67 92 114 
     Gender 
    
Male 27 50 69 78 
Female 5 17 23 36 
     Age-years 
    
Range-mean 32-76 (51) 48-76 (62) 47-82 (63) 45-83 (65) 
     Treatment TURB* TURB + BCG‡ TURB + BCG  TURB + BCG 
     
Response  
to treatment 
Cured 
Responder (68.6%) Responder (54.3%) 
Recurrence 
(42.4%)  
No response 
(31.3%) 
No response 
(45.6%) 
Upstaging (67.5) 
     
Follow-up 
Diagnosis 
Cured 
Ta, low grade, n = 
46 
T1, low grade, n = 
50 
Recurrent T1, n = 
37 
T1, high grade, n = 
21 
T1, high grade, n = 
30 
T1-T3, n = 77 
   
T2-T4, n = 12 
 
________________________________________________________________________ 
     *TURB, transurethral resection of a bladder tumour; ‡ BCG, intravesical instillation of 
bacillus Calmette Guerin. 
 
        
Response to treatment was either good 
response with no recurrence or residual diseases in 
the 3 years follow-up, or non-responder with repeated 
recurrences, upgrading, or upstaging. According to 
response criteria, the 305 patients were categorised 
into 6 groups in consideration of initial diagnosis and 
endpoint of being responder or non-responder. All 
patient’s tissue samples at initial diagnosis and at last 
follow-up were studied for Twist 2 expression by 
immunohistochemistry, the follow-up groups were: 
group1, low grade Ta responder (n = 32); group2, 
High grade Ta non-responder (n = 46); group3, high 
grade Ta non-responder (n = 21); group 4,low grade 
T1 responder (n = 50),group 5, Low grade Ta non-
responder (n = 42), group 6, high grade T1 non-
responder (n = 114) (Table 2).  
Table 2: Twist2 expression in non-muscle invasive bladder 
cancer at baseline in the intention-to-treat and at follow up with 
correlation to response to BCG therapy* 
Group 
 
Twist 2 expression at initial diagnosis Twist2 expression at final  follow-up p
 § 
characteristics no Range Mean ± SD¶
 
Score†
 
Range Mean ± SD Score value 
_________________    _____________________________    _____________________________ ____ 
1.Ta low grade 32 0 0 Negative 0       0 Negative 0.001 
responder ‡
 
                 2.Ta high 
grade 
46 
3-13 1 ± 1    Low 3-6     3 ± 1    low 0.001 
responder 
 
                3.Ta high 
grade 21 21-30 26 ± 2 Medium 27-38      35 ± 1   Medium 0.001 
nonresponder‡ 
                 4. T1 low grade 50 25-36 27 ± 3 Medium 20-25     23 ± 1 Medium 0.001 
responder 
                 5.T1 low grade 42 45-55 50 ± 1    High 60-75     65 ± 1    High 0.001 
nonresponder 
                 6. T1 high 
grade 114 57-83 65 ± 3    High 74-92      88 ± 3     High 0.001 
nonresponder 
                  
*Expression of Twist2 by immunohistochemistry was evaluated at initial diagnosis and final 
follow-up of Ta-T1 non-muscle invasive bladder cancer, patients were treated with Trans-
urethral resection and intravesical BCG for 3 courses, at the end of follow-up patients were 
stratifies into 6 groups according to response to treatment. ‡ Response was assessed at 
the final follow-up, responder was identified as complete response after treatment, 
Responders are patients who had complete response with no or minimal residual disease, 
nonresponders are patients who received maximum of three courses of transurethral 
resection of a tumour and three courses of intravesical instillation of BCG, this patient had 
upgraded, upstaging, and or repeated recurrences. †Twist2 expression score was 
measured according to the percentage of cytoplasmic and nuclear staining: negative 
staining, low score 1-15%, medium 15-40%, high 40-100 % positive.    The P value was 
calculated with the use of chi-square test, P= 0.001 was statistically significant. ¶ SD 
standard deviation.  BCG; Bacillus Chalmette Guerin intravesical installation. 
 
 
Immunohistochemistry 
Total number of cases was of 305 patients; 
tissue samples that were taken by TUR-BT in the 
initial diagnosis and in the follow up and were 
examined for expression of Twist2 by 
immunohistochemistry (IHC), Normal control were 
tissue samples of patients having normal urothelial 
tissue and had not bladder cancer or other 
malignancies (n =10), positive control were muscle 
invasive urothelial bladder cancer who underwent 
cystectomy (n = 10) (Table 3).  
Table 3: Clinical features and Twist2 expression in the negative 
and positive control groups 
Group  Number 
Age Range 
(mean) Gender 
Twist2 expression 
   
Male Female Range Mean ± SD Score 
Normal 
urothelium 10 58-76 (67) 10          0 0 0 Negative 
Muscle 
invasive T2 10 57-76 (62) 8            2 86-98 95±4 High 
SD: standard deviation. 
 
Tissue samples at the initial diagnosis and in 
the following periods were fixed for 24 hours in 10% 
neutral buffered formalin solution and then processed 
for preparing paraffin blocks. Tissue samples were 
examined for histopathological evaluation with 
Hematoxylin and eosin stain and evaluated according 
to the international histological classification of urinary 
bladder tumours of WHO-1999, tumour grade 
according to WHO grading system, 2004, and tumour 
stage according to TNM staging system of UICC-2004 
2015. 
Paraffin-embedded sections of 4mm 
thickness were processed using Anti-Twist2 
concentrated antibody (Abcam, ab 57997, USA), 
antigen retrieval was performed in all cases by steam-
heating the slides in 1 mmol/l solution (pH 9.0) for 45 
min. After blocking of endogenous biotin, staining was 
performed using an automated immunostainer (Ultra 
Benchmark, Ventana, USA), followed by detection 
using Ultraview detection Kid (Ventana, USA). 
Positive and negative control sections were used for 
each assay. 
 
Immunohistochemistry scoring 
The entire section was examined to find the 
area with maximum positivity, and stained nuclei for 
Twist2, positively stained cytoplasm and nuclei were 
scored using the 40X objective in 20 fields. 
Immunohistochemistry evaluation was done by two 
independent observers. For evaluation of a Twist2 
expression, each slide was scored according to the 
percentage of positively stained cytoplasm and 
nuclear staining. The following ranges were used: 
negative score was that to cells not stained, low score 
was that 1 to 15% positive cytoplasmic stain, medium 
score was to 15-40% stain, high expression score was 
to over 40% cytoplasmic expression associated with 
nuclear expression, normal urothelium was negative 
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for Twist2 expression, muscle-invasive urothelial 
carcinoma showed high expression of Twist2 (Figure 
1). Negative external control was done by omitting 
primary antibodies. The acquisition of images was 
done with Nikon Eclipse E600 software program Lucia 
5. 
 
Figure 1: Immunohistochemical (IHC) staining of Twist2 expression 
on paraffin-embedded tissues of non-muscle invasive bladder 
carcinoma. No expression of Twist2 could be seen in normal 
urothelial tissues, while positive expressions of Twist2 have mainly 
localised in the cytoplasm in high-grade Ta, and in both cytoplasm 
an nucleus of high-grade T1 and T2. Magnitude ×200, ×400. (a) 
High-grade Ta, positive for Twist2, with medium expression, IHC 
x200; (b) Low-grade Ta, positive for Twist2, with low expression, 
IHC, x200; (c) High-grade Ta, positive for Twist2, with high 
expression, IHC x200; (d) Low grade papillary Ta, positive for 
Twist2, with low expression, IHC x 400; (e) High grade T1, positive 
nuclear and cytoplasmic staining with overexpression, IHC x200; (f) 
High grade T1, Positive for Twist2,with overexpression, IHC x400; 
(g) High grade T1, Positive for Twist2,with overexpression, IHC 
x200; (h) muscle invasive carcinoma T2, highly positive for twist2, 
with overexpression, IHC x200 
 
Statistical analysis 
A descriptive study of variables in the study 
cohort was done; Chi-square test was performed to 
compare categorical variables with the expression of 
Twist2, dependent variables were recurrence and 
progression-free survival. Differences between 
categories were evaluated using a log-rank test. To 
determine the way by which a tumour was not 
responding to BCG intravesical immunotherapy, 
recurrence, and how tumour progression was affected 
by upregulation of Twist2 expression, a Cox’s 
proportional hazards analysis was performed. A p < 
0.05 was accepted as statistically significant. 
Unavailable Cox regression analysis was performed 
with theTwist2 marker treated as a continuous 
variable, as proposed by Almman et al., [15] and 
Keegan et al., [16], trying to avoid extreme bias. The 
expression of Twist2 variables was analysed in 
function of recurrence-free and progression-free 
survival in response to treatment. 
 
 
Results 
 
The 305 patients with NMIBC were 224 men 
and 81 women, with age ranging from 32 to 83 years; 
patients with Ta tumors were 99 cases, 32 with low-
grade papillary tumor, and 67 with high grades Ta; 
patients with T1 amounted to 206 cases, 92 of low 
grade, and 104 were high grade (Table1). The 
expression of the Twist2 in the tissue samples was 
measured in the initial pathological diagnosis as well 
as in the follow-up, Patients were categorised 
according to initial diagnosis and final diagnosis in the 
follow up after therapy with TURB alone or TURB and 
intravesical BCG for 2-3 courses. Clinical data 
reported cure, recurrence, upgrading, and upstaging, 
during the 3 follow-up years, tumour responded to 
therapy was considered responder, non-responders 
were the tumours that showed upgrading and 
upstaging (Table 2). IHC for expression of Twist2 was 
done in the initial diagnosis, and in the final follow-up, 
patients were categorised into six groups (Table 3). 
Interpretation of the Twist2 expression showed that 
the higher is the stage and grade of a tumour, the 
higher the Twist2 expression scores. Patients who did 
not respond to treatment and had upgrading and 
upstaging showed higher expression of Twist2 in the 
initial diagnosis the more likely the poor response 
therapy, these findings were observed in groups 3,5, 
and 6 who were high-grade Ta, part of low-grade T1, 
and high-grade T1. High score at initial diagnosis in 
patients with high-grade T1 was correlated with non-
responsiveness to therapy and upstaging to MIBC. 
Low-grade Ta papillary tumours had a low score in the 
initial and follow-up diagnosis and had a good 
prognosis.  
High grade Ta tumor were two subdivisions, 
those with low medium score in the initial diagnosis (n 
= 47) who had responded to therapy and had the 
same low medium score in the follow up, the second 
subdivision were those who had high medium score in 
the initial diagnosis (n = 33), they were upstaged to 
high-grade T1 in the follow-up. Comparison between 
mean values of Twist2 expression in initial diagnosis 
of NMIBC and MIBC was highly significant (0.001), 
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comparison between mean values of Twist2 
expression in initial diagnosis of NMIBC and non-
responders that had upstaged and upgraded in the 
follow-up was highly significant (0.001) (Table
 
2) 
Univariable analysis of Twist2 expression in the initial 
diagnosis in relation to tumor grade and stage was 
highly significant (P 0.001); univariable analysis of 
Twist2 expression in relation to sex and gender was 
insignificant. Univariate logistic regression model 
showing Twist2 Expression measured at initial 
diagnosis is a predictor of disease prognosis (P-value 
0.002), Adjusted R Square (0.571), odds ratio (1.416) 
(Table 4) 
Table 4: Univariate logistic regression model showing Twist2 
measured at initial diagnosis as a predictor of disease 
prognosis 
 
 
Adjusted  B P value Odds ratio 95% CI 
 
R Square 
     Twist2  0.571 0.348 0.002 1.416 1.138-1.761 
expression at  
     initial diagnosis 
             
 
 
Discussion 
 
Epithelial-to-mesenchymal transition (EMT) is 
characterised by loss of cellular adhesion and polarity 
and is responsible for cancer metastasis and 
upstaging, EMT regulates urothelial tumour 
progression and sensitivity to drug therapy [16].
 
The 
present study showed that the Twist2 which is one of 
EMT transcriptional repressors of E-cadherin when 
measured at initial diagnosis of NMIBC would indicate 
a response to drug therapy, progression, upgrading 
and upstaging. Twist2 was reported to be good 
prognostic markers for tumour progression in 
urothelial bladder cancer [6] [7] [8] [9] [16]. The 
present study explored the significance of 
measurement of Twist2 expression by IHC at initial 
diagnosis of NMIBC and at follow up following 
treatment with TURT and intravesical BCG therapy, 
our finding showed that Twist2 expression score is a 
predictive marker for tumor response to therapy and 
would indicate future favorable response or 
progression, present work is the first study to show 
the significance of Twist2 expression in NMIBC to 
predict response to treatment. Overexpression and 
high medium Twist2 expression score was a 
determinant factor for non-response to therapy, 
upgrading and upstaging; overexpression of Twist2 
with over 40% score was significant with a p-value (p 
< 0.001). Previous reports show that heterogeneous 
nuclear expression of Twist2 in cancer tissue will 
indicate upstaging, progression, metastases, and poor 
survival [2] [3] [4] [5] [6] [10] [11] [12] [13]. Present 
results on the cytoplasmic and nuclear expression of 
Twist2 confirmed the previous reports. There was a 
significant difference in the expression of Twist2 in 
NMIUBC and positive control of MIUBC. Using the 
ROC curve for the diagnostic index of Twist2 with a 
cut-off > 40, area under the ROC curve was 0.994 
with a sensitivity of 100 and specificity of 97.5. The 
positive predictive value was 87, and the negative 
predictive value was 100. The percentage of cases 
that had upstaged or upgraded in the follow-up 
assessment amounted to 62.95%. The univariate 
logistic regression model showing Twist2 expression 
measured at first as a predictor of disease 
progression showed that the adjusted R square was 
0.571, the p-value was 0.002, the Odds ratio was 
1.416 with 95% confidence interval of 1.138-1.761. 
Present results are by previous studies that showed 
the high positive expression of Twist2 indicating 
progression, metastases and poor survival in 
carcinoma of the bladder and other cancers as breast 
cancer, colorectal cancer, and ovarian cancer [5] [9] 
[10] [11] [12].
 
In conclusion, the high expression of Twist2 
with intense cytoplasmic and nuclear staining with 
duplication or triplication of its value in the follow-up 
for patients with NMIUBC indicated recurrence, 
upstaging and progression of Ta and T1 tumours and 
unfavourable response to intravesical instillation of 
BCG. The study concluded that Twist2 expression in 
the initial diagnosis and the follow-up of treatment of 
NMIBC might be useful for stratifying patients with Ta 
and T1 into risk categories. The results may have an 
important clinical implication. Twist2 as a marker for 
EMT would be considered as a tumor marker to 
predict bladder cancer pathway.  
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